- Home
- MNOV vs IKNA Comparison
MNOV vs IKNA Comparison
Compare MNOV & IKNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MNOV
- IKNA
- Stock Information
- Founded
- MNOV 2000
- IKNA 2016
- Country
- MNOV United States
- IKNA United States
- Employees
- MNOV N/A
- IKNA N/A
- Industry
- MNOV Biotechnology: Pharmaceutical Preparations
- IKNA Biotechnology: Pharmaceutical Preparations
- Sector
- MNOV Health Care
- IKNA Health Care
- Exchange
- MNOV Nasdaq
- IKNA Nasdaq
- Market Cap
- MNOV 68.2M
- IKNA 63.7M
- IPO Year
- MNOV 2005
- IKNA 2021
- Fundamental
- Price
- MNOV $1.28
- IKNA $1.37
- Analyst Decision
- MNOV Strong Buy
- IKNA Strong Buy
- Analyst Count
- MNOV 2
- IKNA 1
- Target Price
- MNOV $7.00
- IKNA $4.00
- AVG Volume (30 Days)
- MNOV 17.6K
- IKNA 63.1K
- Earning Date
- MNOV 08-07-2025
- IKNA 08-07-2025
- Dividend Yield
- MNOV N/A
- IKNA N/A
- EPS Growth
- MNOV N/A
- IKNA N/A
- EPS
- MNOV N/A
- IKNA N/A
- Revenue
- MNOV N/A
- IKNA N/A
- Revenue This Year
- MNOV N/A
- IKNA N/A
- Revenue Next Year
- MNOV N/A
- IKNA N/A
- P/E Ratio
- MNOV N/A
- IKNA N/A
- Revenue Growth
- MNOV N/A
- IKNA N/A
- 52 Week Low
- MNOV $1.12
- IKNA $0.97
- 52 Week High
- MNOV $2.55
- IKNA $1.94
- Technical
- Relative Strength Index (RSI)
- MNOV 43.16
- IKNA 55.10
- Support Level
- MNOV $1.32
- IKNA $1.31
- Resistance Level
- MNOV $1.38
- IKNA $1.42
- Average True Range (ATR)
- MNOV 0.04
- IKNA 0.05
- MACD
- MNOV 0.00
- IKNA -0.00
- Stochastic Oscillator
- MNOV 25.00
- IKNA 51.24
About MNOV Medicinova Inc
MediciNova Inc is a biopharmaceutical company. The company acquires and develops small-molecule therapeutics for the treatment of diseases with unmet medical needs with a specific focus on the U.S. market. Its products portfolio includes therapeutics such as MN-001, MN-166, MN-221 etc. The firm's current strategy is to focus its development activities on therapeutics for neurological disorders and fibrotic diseases.
About IKNA Ikena Oncology Inc.
Ikena Oncology Inc is a targeted oncology company developing precision therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the Hippo and RAS onco-signaling network. Its targeted oncology product candidate, IK-930, is an oral small-molecule inhibitor of the transcriptional enhanced associate domain, or TEAD, a transcription factor in the Hippo signaling pathway, a known oncogenic pathway that also drives resistance to multiple targeted and chemotherapies. Its other product candidates are IK-175 and IK-595.